Coxsackie IgG-/IgA-antibodies

Coxsackie-IgG Type A7 (IFT) detects long-lasting antibodies to Coxsackievirus A7 and is best viewed as evidence of past exposure, not proof of a current infection. Because IFT is assay-specific and enteroviruses can cross-react, use your lab’s cutoffs and clinical context. For suspected acute disease, pair serology with PCR/NAAT (throat/stool/CSF/lesion) and/or look for a fourfold rise in IgG on paired sera 2–4 weeks apart; IgM may support recent exposure but is less reliable than PCR for timing. In the absence of symptoms, elevated IgG usually needs no treatment. If symptomatic, care is typically supportive while ruling in/out other causes.

Coxsackie-IgG Type B1 (IFT) detects long-lasting antibodies to Coxsackievirus B1 and mainly indicates past exposure, not an active infection. Because IFT methods and cutoffs differ and cross-reactivity among enteroviruses can occur, rely on your lab’s ranges and your clinical picture. For suspected acute disease, pair serology with PCR/NAAT (throat/stool/CSF/lesion) and consider paired sera to look for a fourfold IgG rise over 2–4 weeks; IgM may suggest recent exposure but is less specific than PCR for timing. Coxsackie B viruses can involve the heart (myopericarditis), meninges, or pleura/pancreas—seek evaluation if symptoms fit. In the absence of symptoms, an elevated IgG usually needs no treatment.